Selected research
Market Structure
Global Oligonucleotide Therapy-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Oligonucleotide Therapy-based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Oligonucleotide Therapy-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Oligonucleotide Therapy-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Oligonucleotide Therapy-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Oligonucleotide Therapy-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Oligonucleotide Therapy-based Drug include Sobi, Novartis, Pfizer, Biogen, Sylentis, Silence Therapeutics, Secarna, Sarepta Therapeutics and Regulus Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Oligonucleotide Therapy-based Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Oligonucleotide Therapy-based Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Oligonucleotide Therapy-based Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Oligonucleotide Therapy-based Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Oligonucleotide Therapy-based Drug Segment by Company
Sobi
Novartis
Pfizer
Biogen
Sylentis
Silence Therapeutics
Secarna
Sarepta Therapeutics
Regulus Therapeutics
ProQR
Nippon Shinyaku
Moderna Therapeutics
MiNA Therapeutics
Jazz Pharmaceuticals
Ionis Pharmaceuticals
Dicerna
CureVac
BioNTech
Arrowhead
Alnylam
Oligonucleotide Therapy-based Drug Segment by Type
mRNA
siRNA
Antisense Oligonucleotides (ASO)
Oligonucleotide Therapy-based Drug Segment by Application
hATTR
Neuromuscular Diseases
COVID-19
Other
Oligonucleotide Therapy-based Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapy-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapy-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapy-based Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Oligonucleotide Therapy-based Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oligonucleotide Therapy-based Drug industry.
Chapter 3: Detailed analysis of Oligonucleotide Therapy-based Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotide Therapy-based Drugrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
List of Tables
Table 1. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032
Table 2. Key Players of mRNA
Table 3. Key Players of siRNA
Table 4. Key Players of Antisense Oligonucleotides (ASO)
Table 4. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032
Table 5. Key Players of hATTR
Table 6. Key Players of Neuromuscular Diseases
Table 7. Key Players of COVID-19
Table 8. Key Players of Other
Table 9. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032
Table 10. Global Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & (US$ Million)
Table 11. Global Oligonucleotide Therapy-based Drug Market Share by Region (2021-2026)
Table 12. Global Oligonucleotide Therapy-based Drug Market Size by Region (2027-2032) & (US$ Million)
Table 13. Global Oligonucleotide Therapy-based Drug Market Share by Region (2027-2032)
Table 14. Oligonucleotide Therapy-based Drug Industry Trends
Table 15. Oligonucleotide Therapy-based Drug Industry Drivers
Table 16. Oligonucleotide Therapy-based Drug Industry Opportunities and Challenges
Table 17. Oligonucleotide Therapy-based Drug Industry Restraints
Table 18. Global Oligonucleotide Therapy-based Drug Revenue by Company (US$ Million) & (2021-2026)
Table 19. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Company (2021-2026)
Table 20. Global Oligonucleotide Therapy-based Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
Table 21. Global Oligonucleotide Therapy-based Drug Key Company Head Office and Area Served
Table 22. Global Oligonucleotide Therapy-based Drug Company, Product Type & Application
Table 23. Global Oligonucleotide Therapy-based Drug Company Establishment Date
Table 24. Global Company Market Concentration Ratio (CR5 and HHI)
Table 25. Global Oligonucleotide Therapy-based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 26. Global Oligonucleotide Therapy-based Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 27. Global Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & (US$ Million)
Table 28. Global Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032) & (US$ Million)
Table 29. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Type (2021-2026)
Table 30. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Type (2027-2032)
Table 31. Global Oligonucleotide Therapy-based Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 32. Global Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & (US$ Million)
Table 33. Global Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032) & (US$ Million)
Table 34. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Application (2021-2026)
Table 35. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Application (2027-2032)
Table 36. Sobi Company Information
Table 37. Sobi Business Overview
Table 38. Sobi Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 39. Sobi Oligonucleotide Therapy-based Drug Product Portfolio
Table 40. Sobi Recent Development
Table 41. Novartis Company Information
Table 42. Novartis Business Overview
Table 43. Novartis Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 44. Novartis Oligonucleotide Therapy-based Drug Product Portfolio
Table 45. Novartis Recent Development
Table 46. Pfizer Company Information
Table 47. Pfizer Business Overview
Table 48. Pfizer Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 49. Pfizer Oligonucleotide Therapy-based Drug Product Portfolio
Table 50. Pfizer Recent Development
Table 51. Biogen Company Information
Table 52. Biogen Business Overview
Table 53. Biogen Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 54. Biogen Oligonucleotide Therapy-based Drug Product Portfolio
Table 55. Biogen Recent Development
Table 56. Sylentis Company Information
Table 57. Sylentis Business Overview
Table 58. Sylentis Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 59. Sylentis Oligonucleotide Therapy-based Drug Product Portfolio
Table 60. Sylentis Recent Development
Table 61. Silence Therapeutics Company Information
Table 62. Silence Therapeutics Business Overview
Table 63. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 64. Silence Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
Table 65. Silence Therapeutics Recent Development
Table 66. Secarna Company Information
Table 67. Secarna Business Overview
Table 68. Secarna Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 69. Secarna Oligonucleotide Therapy-based Drug Product Portfolio
Table 70. Secarna Recent Development
Table 71. Sarepta Therapeutics Company Information
Table 72. Sarepta Therapeutics Business Overview
Table 73. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 74. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
Table 75. Sarepta Therapeutics Recent Development
Table 76. Regulus Therapeutics Company Information
Table 77. Regulus Therapeutics Business Overview
Table 78. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 79. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
Table 80. Regulus Therapeutics Recent Development
Table 81. ProQR Company Information
Table 82. ProQR Business Overview
Table 83. ProQR Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 84. ProQR Oligonucleotide Therapy-based Drug Product Portfolio
Table 85. ProQR Recent Development
Table 86. Nippon Shinyaku Company Information
Table 87. Nippon Shinyaku Business Overview
Table 88. Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 89. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Portfolio
Table 90. Nippon Shinyaku Recent Development
Table 91. Moderna Therapeutics Company Information
Table 92. Moderna Therapeutics Business Overview
Table 93. Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 94. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
Table 95. Moderna Therapeutics Recent Development
Table 96. MiNA Therapeutics Company Information
Table 97. MiNA Therapeutics Business Overview
Table 98. MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 99. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
Table 100. MiNA Therapeutics Recent Development
Table 101. Jazz Pharmaceuticals Company Information
Table 102. Jazz Pharmaceuticals Business Overview
Table 103. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 104. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
Table 105. Jazz Pharmaceuticals Recent Development
Table 106. Ionis Pharmaceuticals Company Information
Table 107. Ionis Pharmaceuticals Business Overview
Table 108. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 109. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
Table 110. Ionis Pharmaceuticals Recent Development
Table 111. Dicerna Company Information
Table 112. Dicerna Business Overview
Table 113. Dicerna Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 114. Dicerna Oligonucleotide Therapy-based Drug Product Portfolio
Table 115. Dicerna Recent Development
Table 116. CureVac Company Information
Table 117. CureVac Business Overview
Table 118. CureVac Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 119. CureVac Oligonucleotide Therapy-based Drug Product Portfolio
Table 120. CureVac Recent Development
Table 121. BioNTech Company Information
Table 122. BioNTech Business Overview
Table 123. BioNTech Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 124. BioNTech Oligonucleotide Therapy-based Drug Product Portfolio
Table 125. BioNTech Recent Development
Table 126. Arrowhead Company Information
Table 127. Arrowhead Business Overview
Table 128. Arrowhead Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 129. Arrowhead Oligonucleotide Therapy-based Drug Product Portfolio
Table 130. Arrowhead Recent Development
Table 131. Alnylam Company Information
Table 132. Alnylam Business Overview
Table 133. Alnylam Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 134. Alnylam Oligonucleotide Therapy-based Drug Product Portfolio
Table 135. Alnylam Recent Development
Table 136. North America Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & (US$ Million)
Table 137. North America Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032) & (US$ Million)
Table 138. North America Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & (US$ Million)
Table 139. North America Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032) & (US$ Million)
Table 140. North America Oligonucleotide Therapy-based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 141. North America Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
Table 142. North America Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
Table 143. Europe Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & (US$ Million)
Table 144. Europe Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032) & (US$ Million)
Table 145. Europe Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & (US$ Million)
Table 146. Europe Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032) & (US$ Million)
Table 147. Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 148. Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
Table 149. Europe Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
Table 150. China Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & (US$ Million)
Table 151. China Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032) & (US$ Million)
Table 152. China Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & (US$ Million)
Table 153. China Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032) & (US$ Million)
Table 154. Asia Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & (US$ Million)
Table 155. Asia Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032) & (US$ Million)
Table 156. Asia Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & (US$ Million)
Table 157. Asia Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032) & (US$ Million)
Table 158. Asia Oligonucleotide Therapy-based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 159. Asia Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
Table 160. Asia Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
Table 161. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & (US$ Million)
Table 162. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032) & (US$ Million)
Table 163. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & (US$ Million)
Table 164. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032) & (US$ Million)
Table 165. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 166. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
Table 167. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
Table 168. Research Programs/Design for This Report
Table 169. Authors List of This Report
Table 170. Secondary Sources
Table 171. Primary Sources
List of Figures
Figure 1. Oligonucleotide Therapy-based Drug Product Image
Figure 2. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million)
Figure 3. Global Oligonucleotide Therapy-based Drug Market Share by Type: 2025 VS 2032
Figure 4. mRNA Image
Figure 5. siRNA Image
Figure 6. Antisense Oligonucleotides (ASO) Image
Figure 7. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million)
Figure 8. Global Oligonucleotide Therapy-based Drug Market Share by Application: 2025 VS 2032
Figure 9. hATTR Image
Figure 10. Neuromuscular Diseases Image
Figure 11. COVID-19 Image
Figure 12. Other Image
Figure 13. Global Oligonucleotide Therapy-based Drug Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 14. Global Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 15. Global Oligonucleotide Therapy-based Drug Market Share by Region: 2025 VS 2032
Figure 16. Years Considered
Figure 17. Global Oligonucleotide Therapy-based Drug Market Share by Players in 2025
Figure 18. Global Top 5 and 10 Oligonucleotide Therapy-based Drug Players Market Share by Revenue in 2025
Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 20. Global Oligonucleotide Therapy-based Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 21. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Type (2021-2032)
Figure 22. Global Oligonucleotide Therapy-based Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 23. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Application (2021-2032)
Figure 24. North America Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 25. North America Oligonucleotide Therapy-based Drug Market Share by Type (2021-2032)
Figure 26. North America Oligonucleotide Therapy-based Drug Market Share by Application (2021-2032)
Figure 27. North America Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032)
Figure 28. United States Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 29. Canada Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 30. Mexico Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 31. Europe Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 32. Europe Oligonucleotide Therapy-based Drug Market Share by Type (2021-2032)
Figure 33. Europe Oligonucleotide Therapy-based Drug Market Share by Application (2021-2032)
Figure 34. Europe Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032)
Figure 35. Germany Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 36. France Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 37. U.K. Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 38. Italy Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 39. Russia Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 40. Nordic Countries Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 41. China Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 42. China Oligonucleotide Therapy-based Drug Market Share by Type (2021-2032)
Figure 43. China Oligonucleotide Therapy-based Drug Market Share by Application (2021-2032)
Figure 44. Asia Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 45. Asia Oligonucleotide Therapy-based Drug Market Share by Type (2021-2032)
Figure 46. Asia Oligonucleotide Therapy-based Drug Market Share by Application (2021-2032)
Figure 47. Asia Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032)
Figure 48. Japan Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 49. South Korea Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 50. Taiwan Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 51. Southeast Asia Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 52. India Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 53. Australia Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 54. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 55. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Share by Type (2021-2032)
Figure 56. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Share by Application (2021-2032)
Figure 57. South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032)
Figure 58. Brazil Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 59. South Africa Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 60. Saudi Arabia Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 61. Turkey Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 62. Argentina Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 63. UAE Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 64. Egypt Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 65. Chile Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 66. Research Process
Figure 67. Key Executives Interviewed
Scope & coverage.
Types
- mRNA
- siRNA
- Antisense Oligonucleotides (ASO)
Applications
- hATTR
- Neuromuscular Diseases
- COVID-19
- Other
Companies covered
- Sobi
- Novartis
- Pfizer
- Biogen
- Sylentis
- Silence Therapeutics
- Secarna
- Sarepta Therapeutics
- Regulus Therapeutics
- ProQR
- Nippon Shinyaku
- Moderna Therapeutics
- MiNA Therapeutics
- Jazz Pharmaceuticals
- Ionis Pharmaceuticals
- Dicerna
- CureVac
- BioNTech
- Arrowhead
- Alnylam
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Oligonucleotide Therapy-based Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 mRNA
- 1.2.3 siRNA
- 1.2.4 Antisense Oligonucleotides (ASO)
- 1.3 Market Analysis by Application
- 1.3.1 Global Oligonucleotide Therapy-based Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 hATTR
- 1.3.3 Neuromuscular Diseases
- 1.3.4 COVID-19
- 1.3.5 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Oligonucleotide Therapy-based Drug Growth Trends by Region
- 1.5.1 Global Oligonucleotide Therapy-based Drug Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026)
- 1.5.3 Oligonucleotide Therapy-based Drug Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Oligonucleotide Therapy-based Drug Market Dynamics
- 2.1 Oligonucleotide Therapy-based Drug Industry Trends
- 2.2 Oligonucleotide Therapy-based Drug Industry Drivers
- 2.3 Oligonucleotide Therapy-based Drug Industry Opportunities and Challenges
- 2.4 Oligonucleotide Therapy-based Drug Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Oligonucleotide Therapy-based Drug Revenue by Company (2021-2026)
- 3.2 Global Oligonucleotide Therapy-based Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Oligonucleotide Therapy-based Drug Key Company Head office and Area Served
- 3.4 Global Oligonucleotide Therapy-based Drug Company, Product Type & Application
- 3.5 Global Oligonucleotide Therapy-based Drug Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Oligonucleotide Therapy-based Drug Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Oligonucleotide Therapy-based Drug Players Market Share by Revenue in 2025
- 3.6.3 2025 Oligonucleotide Therapy-based Drug Tier 1, Tier 2, and Tier 3
4 Oligonucleotide Therapy-based Drug Market by Type
- 4.1 Global Oligonucleotide Therapy-based Drug Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Oligonucleotide Therapy-based Drug Market Size by Type (2021-2032)
- 4.3 Global Oligonucleotide Therapy-based Drug Market Size Share by Type (2021-2032)
5 Oligonucleotide Therapy-based Drug Market by Application
- 5.1 Global Oligonucleotide Therapy-based Drug Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Oligonucleotide Therapy-based Drug Market Size by Application (2021-2032)
- 5.3 Global Oligonucleotide Therapy-based Drug Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Sobi
- 6.1.1 Sobi Company Information
- 6.1.2 Sobi Business Overview
- 6.1.3 Sobi Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Sobi Oligonucleotide Therapy-based Drug Product Portfolio
- 6.1.5 Sobi Recent Developments
- 6.2 Novartis
- 6.2.1 Novartis Company Information
- 6.2.2 Novartis Business Overview
- 6.2.3 Novartis Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Novartis Oligonucleotide Therapy-based Drug Product Portfolio
- 6.2.5 Novartis Recent Developments
- 6.3 Pfizer
- 6.3.1 Pfizer Company Information
- 6.3.2 Pfizer Business Overview
- 6.3.3 Pfizer Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Pfizer Oligonucleotide Therapy-based Drug Product Portfolio
- 6.3.5 Pfizer Recent Developments
- 6.4 Biogen
- 6.4.1 Biogen Company Information
- 6.4.2 Biogen Business Overview
- 6.4.3 Biogen Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Biogen Oligonucleotide Therapy-based Drug Product Portfolio
- 6.4.5 Biogen Recent Developments
- 6.5 Sylentis
- 6.5.1 Sylentis Company Information
- 6.5.2 Sylentis Business Overview
- 6.5.3 Sylentis Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Sylentis Oligonucleotide Therapy-based Drug Product Portfolio
- 6.5.5 Sylentis Recent Developments
- 6.6 Silence Therapeutics
- 6.6.1 Silence Therapeutics Company Information
- 6.6.2 Silence Therapeutics Business Overview
- 6.6.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
- 6.6.5 Silence Therapeutics Recent Developments
- 6.7 Secarna
- 6.7.1 Secarna Company Information
- 6.7.2 Secarna Business Overview
- 6.7.3 Secarna Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Secarna Oligonucleotide Therapy-based Drug Product Portfolio
- 6.7.5 Secarna Recent Developments
- 6.8 Sarepta Therapeutics
- 6.8.1 Sarepta Therapeutics Company Information
- 6.8.2 Sarepta Therapeutics Business Overview
- 6.8.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
- 6.8.5 Sarepta Therapeutics Recent Developments
- 6.9 Regulus Therapeutics
- 6.9.1 Regulus Therapeutics Company Information
- 6.9.2 Regulus Therapeutics Business Overview
- 6.9.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
- 6.9.5 Regulus Therapeutics Recent Developments
- 6.10 ProQR
- 6.10.1 ProQR Company Information
- 6.10.2 ProQR Business Overview
- 6.10.3 ProQR Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 ProQR Oligonucleotide Therapy-based Drug Product Portfolio
- 6.10.5 ProQR Recent Developments
- 6.11 Nippon Shinyaku
- 6.11.1 Nippon Shinyaku Company Information
- 6.11.2 Nippon Shinyaku Business Overview
- 6.11.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Portfolio
- 6.11.5 Nippon Shinyaku Recent Developments
- 6.12 Moderna Therapeutics
- 6.12.1 Moderna Therapeutics Company Information
- 6.12.2 Moderna Therapeutics Business Overview
- 6.12.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
- 6.12.5 Moderna Therapeutics Recent Developments
- 6.13 MiNA Therapeutics
- 6.13.1 MiNA Therapeutics Company Information
- 6.13.2 MiNA Therapeutics Business Overview
- 6.13.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
- 6.13.5 MiNA Therapeutics Recent Developments
- 6.14 Jazz Pharmaceuticals
- 6.14.1 Jazz Pharmaceuticals Company Information
- 6.14.2 Jazz Pharmaceuticals Business Overview
- 6.14.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
- 6.14.5 Jazz Pharmaceuticals Recent Developments
- 6.15 Ionis Pharmaceuticals
- 6.15.1 Ionis Pharmaceuticals Company Information
- 6.15.2 Ionis Pharmaceuticals Business Overview
- 6.15.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
- 6.15.5 Ionis Pharmaceuticals Recent Developments
- 6.16 Dicerna
- 6.16.1 Dicerna Company Information
- 6.16.2 Dicerna Business Overview
- 6.16.3 Dicerna Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Dicerna Oligonucleotide Therapy-based Drug Product Portfolio
- 6.16.5 Dicerna Recent Developments
- 6.17 CureVac
- 6.17.1 CureVac Company Information
- 6.17.2 CureVac Business Overview
- 6.17.3 CureVac Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 CureVac Oligonucleotide Therapy-based Drug Product Portfolio
- 6.17.5 CureVac Recent Developments
- 6.18 BioNTech
- 6.18.1 BioNTech Company Information
- 6.18.2 BioNTech Business Overview
- 6.18.3 BioNTech Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 BioNTech Oligonucleotide Therapy-based Drug Product Portfolio
- 6.18.5 BioNTech Recent Developments
- 6.19 Arrowhead
- 6.19.1 Arrowhead Company Information
- 6.19.2 Arrowhead Business Overview
- 6.19.3 Arrowhead Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.19.4 Arrowhead Oligonucleotide Therapy-based Drug Product Portfolio
- 6.19.5 Arrowhead Recent Developments
- 6.20 Alnylam
- 6.20.1 Alnylam Company Information
- 6.20.2 Alnylam Business Overview
- 6.20.3 Alnylam Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.20.4 Alnylam Oligonucleotide Therapy-based Drug Product Portfolio
- 6.20.5 Alnylam Recent Developments
7 North America
- 7.1 North America Oligonucleotide Therapy-based Drug Market Size (2021-2032)
- 7.2 North America Oligonucleotide Therapy-based Drug Market Size by Type
- 7.2.1 North America Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
- 7.2.2 North America Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032)
- 7.2.3 North America Oligonucleotide Therapy-based Drug Market Share by Type (2021-2032)
- 7.3 North America Oligonucleotide Therapy-based Drug Market Size by Application
- 7.3.1 North America Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
- 7.3.2 North America Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032)
- 7.3.3 North America Oligonucleotide Therapy-based Drug Market Share by Application (2021-2032)
- 7.4 North America Oligonucleotide Therapy-based Drug Market Size by Country
- 7.4.1 North America Oligonucleotide Therapy-based Drug Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
- 7.4.3 North America Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
- 7.4.4 North America Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Oligonucleotide Therapy-based Drug Market Size (2021-2032)
- 8.2 Europe Oligonucleotide Therapy-based Drug Market Size by Type
- 8.2.1 Europe Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
- 8.2.2 Europe Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032)
- 8.2.3 Europe Oligonucleotide Therapy-based Drug Market Share by Type (2021-2032)
- 8.3 Europe Oligonucleotide Therapy-based Drug Market Size by Application
- 8.3.1 Europe Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
- 8.3.2 Europe Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032)
- 8.3.3 Europe Oligonucleotide Therapy-based Drug Market Share by Application (2021-2032)
- 8.4 Europe Oligonucleotide Therapy-based Drug Market Size by Country
- 8.4.1 Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
- 8.4.3 Europe Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
- 8.4.4 Europe Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Oligonucleotide Therapy-based Drug Market Size (2021-2032)
- 9.2 China Oligonucleotide Therapy-based Drug Market Size by Type
- 9.2.1 China Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
- 9.2.2 China Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032)
- 9.2.3 China Oligonucleotide Therapy-based Drug Market Share by Type (2021-2032)
- 9.3 China Oligonucleotide Therapy-based Drug Market Size by Application
- 9.3.1 China Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
- 9.3.2 China Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032)
- 9.3.3 China Oligonucleotide Therapy-based Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Oligonucleotide Therapy-based Drug Market Size (2021-2032)
- 10.2 Asia Oligonucleotide Therapy-based Drug Market Size by Type
- 10.2.1 Asia Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
- 10.2.2 Asia Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032)
- 10.2.3 Asia Oligonucleotide Therapy-based Drug Market Share by Type (2021-2032)
- 10.3 Asia Oligonucleotide Therapy-based Drug Market Size by Application
- 10.3.1 Asia Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
- 10.3.2 Asia Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032)
- 10.3.3 Asia Oligonucleotide Therapy-based Drug Market Share by Application (2021-2032)
- 10.4 Asia Oligonucleotide Therapy-based Drug Market Size by Country
- 10.4.1 Asia Oligonucleotide Therapy-based Drug Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
- 10.4.3 Asia Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
- 10.4.4 Asia Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Type
- 11.2.1 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Application
- 11.3.1 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country
- 11.4.1 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst